Viridian Therapeutics (VRDN) announced that enrollment is complete in REVEAL-1 and REVEAL-2, phase 3 clinical trials for VRDN-003 in patients with active and chronic TED, respectively. VRDN-003 is a subcutaneously delivered, half-life extended, monoclonal antibody targeting the insulin-like growth factor-1 receptor.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics files automatic mixed securities shelf
- Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating
- Viridian Therapeutics price target raised to $32 from $28 at Oppenheimer
- Optimistic Outlook for Viridian Therapeutics: Strategic Advances and Market Potential in TED Treatment
- Viridian Therapeutics price target lowered to $26 from $27 at Wells Fargo